Bill Sponsor
Senate Bill 1548
117th Congress(2021-2022)
ENACT Act of 2021
Introduced
Introduced
Introduced in Senate on May 11, 2021
Overview
Text
Introduced
May 11, 2021
Latest Action
May 11, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1548
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
New Mexico
Democrat
Arizona
Republican
Arkansas
Republican
Louisiana
Democrat
Massachusetts
Democrat
Michigan
Democrat
Minnesota
Republican
Mississippi
Democrat
New Jersey
Republican
Oklahoma
Democrat
Pennsylvania
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Equity in Neuroscience and Alzheimer's Clinical Trials Act of 2021 or the ENACT Act of 2021

This bill sets out activities and requirements to increase the participation of underrepresented populations in research and clinical trials for Alzheimer's disease and related dementias.

Specifically, the National Institute on Aging (NIA) must establish and provide technical assistance to Alzheimer's research centers located in areas with higher concentrations of minority groups. These centers must

  • establish diagnostic and treatment clinics designed to serve minority, rural, and other underserved populations;
  • operate clinical trials; and
  • carry out public outreach to encourage members of minority populations to participate in clinical trials and research.

Additionally, the NIA must disseminate information to members of minority populations about participating in clinical trials and take other actions to enhance diversity with respect to the Alzheimer's research that it conducts or supports.

The bill also directs the NIA to increase diversity among Alzheimer's researchers by encouraging the participation of individuals who are from groups that are underrepresented in clinical, behavioral, and social sciences.

Text (1)
Actions (2)
05/11/2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
05/11/2021
Introduced in Senate
Public Record
Record Updated
Mar 8, 2023 8:12:26 PM